RNA replication and amplification have broad applications across biomedicine, but current methods are limited by a reliance on inefficient, multi-step protocols.
Researchers at Stanford have developed an oxygen-generating, collagen-based cryogel bioscaffold to improve islet cell transplantation for the treatment of diabetes. Type 1 diabetes, which affects millions of people, is currently treated by daily injection of insulin.
Researchers at Stanford have developed reactive oxygen species (ROS) sensing nanoparticles (NP) that can amplify Raman fingerprint signals and detect ROS changes.
Engineers at Stanford have invented a smart toilet platform that will autonomously monitor excreted waste from humans. We describe easily deployable hardware and software for the long-term analysis of a user's excreta through data collection and models of human health.
Researchers in Prof. Stephen Quake's laboratory have developed a CRISPER-Cas-based targeted endonuclease system designed to treat latent viral infections by attacking the viral genome.
Stanford researchers have developed a method for manufacturing a UV curable epoxy micro lens. Apertures of arbitrary size can be manufactured for micro lenses using this method.
Dr. Francis Blankenberg has developed a method to prevent the spread of Listeria and other obligate intracellular pathogens, including mycobacterium marinum, chlamydia trachomatis and parasitic infections.
Disease indication - Cancer, specifically:
-highly mutated cancers, including the ~20% of cancer with BAF complex mutations
-combination therapy with ATR inhibitors
Stanford researchers have demonstrated the application of pulsed Focused Ultrasound (pFUS), to non-invasively enhance the function and engraftment of pancreatic islets following transplantation.
The Hong Neurotechnology Lab at Stanford University developed ultrasound-activated nanoscopic light emitters (mechanoluminescent nanoparticles) that are delivered via the blood stream, unlike conventional optogenetics approaches that require invasive fiber optic implants.
Researchers at Stanford have developed agents to enhance the therapeutic efficacy of a variety of anti-cancer therapeutics. Cell loss by apoptosis occurs in normal development and in tumor environments.
Researchers in Prof. A.C. Matin's laboratory have developed a versatile exosome (extracellular vesicle, "EV") drug delivery platform that can selectively target therapeutic agents to tumors or other tissues that overexpress extracellular receptors.